Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Oliver Mikse"'
Autor:
Kwok-Kin Wong, Andrew L. Kung, Geoffrey I. Shapiro, Jeffrey A. Engelman, Norman E. Sharpless, Pasi A. Janne, Jacob B. Reibel, Liang Chen, Sue-Ann Woo, Abigail Altabef, Xiaohong Tan, Yuchuan Wang, Katherine Cheng, Tanya Tupper, Oliver Mikse, Esra Akbay, Zhao Chen
PDF file - 806K, Supplemental Figure 1. MRI scans at the indicated time points showing tumor burden in EML4-ALK lung cancer mice treated by crizotinib. Multiple scans from a total of 4 mice are shown. Supplemental Figure 2. Representative MRI images
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66dfddd4f3d8ffc44705be49a9521f64
https://doi.org/10.1158/1078-0432.22449362
https://doi.org/10.1158/1078-0432.22449362
Autor:
Kwok-Kin Wong, Andrew L. Kung, Geoffrey I. Shapiro, Jeffrey A. Engelman, Norman E. Sharpless, Pasi A. Janne, Jacob B. Reibel, Liang Chen, Sue-Ann Woo, Abigail Altabef, Xiaohong Tan, Yuchuan Wang, Katherine Cheng, Tanya Tupper, Oliver Mikse, Esra Akbay, Zhao Chen
Purpose: To extend the results of a phase III trial in patients with non–small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion.Experimental Design: We conducted a co-clinical trial in a mouse model comparing the ALK inhibitor crizot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b56e100cc467f8706b8b29828154c3
https://doi.org/10.1158/1078-0432.c.6521633
https://doi.org/10.1158/1078-0432.c.6521633
Autor:
Oliver Mikse, Tahirih L. Lamothe, Lisa M Olson, Nidhi Jain, Jennifer L. Proctor, Ryan Knihtila, Sean McDonough, John C. Davis, Anthony E. Boitano, Rahul Palchaudhuri, Michael P. Cooke, Ganapathy N. Sarma, Bradley R. Pearse, Prashant raj Bhattarai, Leanne Lanieri, Junia Dushime, Kellie Latimer
Publikováno v:
Transplantation and Cellular Therapy. 27:S49-S50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1be6db879b36491aaefce34d13b1d033
https://doi.org/10.1016/s2666-6367(21)00079-8
https://doi.org/10.1016/s2666-6367(21)00079-8
Autor:
Esra A. Akbay, Liang Chen, Peter S. Hammerman, Roderick T. Bronson, Oliver Mikse, Jeremy H. Tchaicha, Kwok-Kin Wong
Publikováno v:
Oncotarget
// Oliver R. Mikse 1,2,3 , Jeremy H. Tchaicha 1,2,3 , Esra A. Akbay 1,2,3 , Liang Chen 1,2,3 , Roderick T. Bronson 4 , Peter S. Hammerman 1,2,5 and Kwok-Kin Wong 1,2,3,6 1 Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b7f2ecfd46928ca03e9771f57797bef
http://europepmc.org/articles/PMC5077968
http://europepmc.org/articles/PMC5077968
Autor:
Tahirih L. Lamothe, Sean McDonough, Prashant raj Bhattarai, Oliver Mikse, Michael P. Cooke, Anthony E. Boitano, Rahul Palchaudhuri, Melissa L. Brooks, Ganapathy N. Sarma, Jennifer L. Proctor, Charlotte Mcdonagh, Geoffrey O. Gillard, Leanne Lanieri, Nidhi Jain, Lena Kien, Anjali Bhat
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S96
For patients with refractory or high-risk hematologic malignancies, like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplant (Allo-HSCT) is a potentially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9610c77dbce618ed391130a813ecff5d
https://doi.org/10.1016/j.bbmt.2019.12.021
https://doi.org/10.1016/j.bbmt.2019.12.021
Autor:
Oliver Mikse, Rachel G. Liao, Nathanael S. Gray, Li Tan, Yvonne Y. Li, Peter S. Hammerman, Kwok-Kin Wong, Jun Wang, Pasi A. Jänne
Publikováno v:
Oncogene
Somatic alterations of Fibroblast Growth Factor Receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d38d2f18da1ac33f6b1f0567c151e62
https://doi.org/10.1038/onc.2014.161
https://doi.org/10.1038/onc.2014.161
Autor:
Anjali Bhat, Michael P. Cooke, Oliver Mikse, Prashant raj Bhattarai, Charlotte F. Mcdonough, Geoff O Gillard, Tahirih L. Lamothe, Sharon L. Hyzy, Rahul Palchaudhuri, Ganapathy N. Sarma, Bradley R. Pearse, Jennifer L. Proctor, Anthony E. Boitano, Sean McDonough, Melissa L. Brooks, Pranoti Sawant
Publikováno v:
Blood. 134:3208-3208
Resetting the immune system through autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to 15 years) with 70-80% progressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aecdbfde49cb22e4f04e4e59a05ec5a1
https://doi.org/10.1182/blood-2019-130752
https://doi.org/10.1182/blood-2019-130752
Autor:
Glenn Dranoff, Gordon J. Freeman, Margaret Soucheray, Camilla L. Christensen, Matthew D. Wilkerson, Mohit Butaney, Lynette M. Sholl, Andrew D. Cherniack, Esra A. Akbay, D. Neil Hayes, Travis J. Cohoon, Kwok-Kin Wong, Shohei Koyama, Julian Carretero, Oliver Mikse, Peter S. Hammerman, Scott J. Rodig, Jeremy H. Tchaicha, Peter E. Fecci, Jacob B. Reibel, Pasi A. Jänne, Geoffrey I. Shapiro, Matthew Meyerson, Ellen M. Beauchamp, Abigail Altabef, Takeshi Shimamura, Trevor J. Pugh
Publikováno v:
Cancer Discovery. 3:1355-1363
The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signature of immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d349fee2b876146c84780b9445679cee
https://doi.org/10.1158/2159-8290.cd-13-0310
https://doi.org/10.1158/2159-8290.cd-13-0310
Autor:
Xiaohong Tan, Tanya Tupper, Oliver Mikse, Esra A. Akbay, Andrew L. Kung, Geoffrey I. Shapiro, Abigail Altabef, Jacob B. Reibel, Kwok-Kin Wong, Liang Chen, Norman E. Sharpless, Katherine A. Cheng, Sue Ann Woo, Yuchuan Wang, Jeffrey A. Engelman, Zhao Chen, Pasi A. Jänne
Purpose: To extend the results of a phase III trial in patients with non–small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion. Experimental Design: We conducted a co-clinical trial in a mouse model comparing the ALK inhibitor crizo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4caa2297d915bfcb2ca7d1b2a8ed2717
Autor:
Timothy A. Lewis, Matthew G. Rees, Mark Hickey, Nicola Tolliday, Patrick W. Faloon, Heidi Greulich, Stuart L. Schreiber, Aviad Tsherniak, Lara Gechijian, Willmen Youngsaye, Luc de Waal, Matthew Meyerson, Monica Schenone, Kwok K. Wong, Angela N. Koehler, Oliver Mikse, Benito Munoz, Alykhan F. Shamji
Publikováno v:
Cancer Research. 74:4596-4596
Recent large sequencing and cancer dependency studies have accelerated the identification of candidate targets for precision medicine. However, the current drug development paradigm starting with target identification and validation can be slow and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87da4b7e7c010eeb80f4498ecbcf178b
https://doi.org/10.1158/1538-7445.am2014-4596
https://doi.org/10.1158/1538-7445.am2014-4596